saxagliptin: Clinical Trials

127 trials of saxagliptin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

96 completed, 16 unknown, 8 terminated, 3 not yet recruiting. 42 Phase 3, 39 Phase 4, 20 Phase 1, 9 Phase 2, 7 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 342Completed 39, Active not recruiting 1, Terminated 1, Unknown 1
Phase 439Completed 23, Unknown 10, Terminated 5, Suspended 1
Phase 120Completed 18, Terminated 1, Withdrawn 1
Phase 29Completed 7, Active not recruiting 1, Not yet recruiting 1
Not applicable7Unknown 4, Completed 1, Recruiting 1, Terminated 1
Early Phase 11Completed 1

Follow saxagliptin: new trials by email Literature Review of saxagliptin trials Research Report on saxagliptin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Restoring Awareness
Saxagliptin (Mylan Pharmaceuticals Inc., NDC: 0378-4706-93) - Vegetative State, Minimally Conscious State
Phase 2Not yet recruitingCasa Colina Hospital and Centers for Healthcare242026-11-152026-11-05
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes - Type 2 Diabetes
Phase 2 / Phase 3Active not recruitingHan Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair6002026-06-152026-08-27
Pattern of Treatment and Outcomes of Locally Advanced Rectal Carcinoma
No Intervention (subjects were previously treated with Onglyza®) - Rectal Carcinoma
Not yet recruitingSohag University1002026-03-012026-01-23
Robson Ten-Group Classification Study of Cesarean Section Rates in Assiut Hospitals
No Intervention (subjects were previously treated with Onglyza®) - Cesarean Section, Maternal Health
Not yet recruitingAssiut University7702025-12-012025-09-26
Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control
Insulin Glargine 100 UNT/ML Pen Injector [Lantus], Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg, Pioglitazone 30mg - Type2diabetes
Phase 3CompletedUniversity of Basrah2432023-11-012025-03-30
Cognitive Protective Effect of Newer Antidiabetic Drugs
Dapagliflozin, Empagliflozin, Canagliflozin - Type 2 Diabetes
UnknownAlexandria University1002022-03-022022-07-26
To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients
dapagliflozin and saxagliptin - Type 2 Diabetes Mellitus
Phase 4CompletedAstraZeneca1962021-04-072024-11-12
SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.
Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill, Empagliflozin or Dapagliflozin Pill - Type 2 Diabetes, Urinary Tract Infections
CompletedUniversity of Pisa602020-10-072025-07-18
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
Canagliflozin, DPP4 inhibitor, Liraglutide - Type 2 Diabetes Mellitus
CompletedAstraZeneca2399902020-05-152024-08-30
Evaluation of Drug Interactions of Saxagliptin With Sildenafil in Healthy Volunteers
Saxagliptin 5mg, Sildenafil 50 mg - Diabetes Mellitus, Type 2, Erectile Dysfunction With Diabetes Mellitus
Not applicableUnknownAin Shams University182019-12-012019-11-20
Tubular Markers in Response to Saxagliptin Therapy
Saxagliptin 5mg - Diabetes Mellitus, Type 2
Phase 4CompletedBeni-Suef University802019-03-012020-08-20
Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin
Dapagliflozin 10 mg, Dapagliflozin 5 mg, Dapagliflozin 10 mg placebo to match - Type 2 Diabetes Mellitus
Phase 3TerminatedAstraZeneca412019-02-272022-05-31
Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus
Dapagliflozin 10mg, Saxagliptin 5mg, Placebo Oral Tablet - Diabetes Mellitus, Type 2, Cardiovascular Diseases
Phase 4TerminatedSabyasachi Sen152018-10-222023-06-05
Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy
Triple combination therapy group, Premixed insulin therapy group - Type 2 Diabetes Mellitus
Phase 4CompletedZhujiang Hospital1302018-10-012024-03-18
Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.
Dapagliflozin 10mg, Saxagliptin 5mg, Saxagliptin 5mg + Dapagliflozin 10 mg - Type2 Diabetes Mellitus
Phase 2CompletedUniversity of Pisa482018-07-242022-11-08
Neuropeptide Y and Sympathovagal Balance
Saxagliptin 5mg, Placebo oral capsule, ergometric test in healthy volunteers - Physical Activity, Sympathetic Nervous System
Early Phase 1CompletedEric Grouzmann72018-06-052019-05-01
Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment
Dapagliflozin 10 mg + Saxagliptin 5 mg, Placebo 1 10 mg + Placebo 2 5 mg - Type 2 Diabetes
Phase 4TerminatedUniversity Hospital Tuebingen42018-02-022020-02-11
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
Dapagliflozin, Saxagliptin, Placebo - Diabetes Mellitus, Type 2
Phase 3CompletedAstraZeneca2562017-10-112024-06-21
Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims
Saxagliptin, Sulfonylurea - Diabetes
CompletedBrigham and Women's Hospital1821262017-09-222023-08-01
A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.
2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR - Type 2 Diabetes Mellitus
Phase 1CompletedAstraZeneca852017-05-292017-08-14

Showing 20 of 127. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 2 (97)  ·  Diabetes Mellitus (14)  ·  Diabetes Mellitus, Type 1 (4)  ·  Glucose Intolerance (4)  ·  Obesity (4)  ·  Heart Failure (3)  ·  Cardiovascular Diseases (2)  ·  Cystic Fibrosis (2)  ·  Insulin Resistance (2)  ·  Prediabetic State (2)  ·  Acute Coronary Syndrome (1)  ·  Albuminuria (1)  ·  Autoimmune Diseases (1)  ·  Coronary Artery Disease (1)  ·  Diabetic Foot (1)

Sponsors

AstraZeneca (64)  ·  Canadian Network for Observational Drug Effect Studies, CNODES (3)  ·  Shanghai Jiao Tong University School of Medicine (3)  ·  Brigham and Women's Hospital (2)  ·  Ram Weiss (2)  ·  The University of Texas Health Science Center at San Antonio (2)  ·  University of Pisa (2)  ·  Ain Shams University (1)  ·  Alexandria University (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Assiut University (1)  ·  Astellas Pharma Inc (1)  ·  Baylor College of Medicine (1)  ·  Beijing Chao Yang Hospital (1)  ·  Beni-Suef University (1)

Countries

United States (54)  ·  Mexico (22)  ·  China (21)  ·  Canada (17)  ·  Germany (14)  ·  Hungary (13)  ·  India (13)  ·  Russia (13)  ·  Poland (12)  ·  United Kingdom (12)  ·  Puerto Rico (11)  ·  South Korea (11)  ·  Argentina (9)  ·  Italy (9)  ·  South Africa (9)

Top investigators

Deborah Price, MSc (7)  ·  Pierre Ernst, MD, MSc (3)  ·  Eitan Kerem, MD (2)  ·  Guang Ning, MD. PHD (2)  ·  Linong Ji, Professor (2)  ·  Peter Ohman, MD (2)  ·  Peter Ohman, MD, PhD (2)  ·  Ralph A DeFronzo, MD (2)  ·  Absalaon D Gutierrez, MD (1)  ·  Ahmed A Elberry, prof (1)  ·  Ahmed F El-Yazbi, PhD (1)  ·  Ambika Babu, MD,MS (1)  ·  Amr El-Feky, MD (1)

Results publications

PMID 27402391, PMID 27033025, PMID 23795975, PMID 21680990, PMID 25414932, PMID 19114612, PMID 21819160, PMID 21871686, PMID 23549864, PMID 23802840, PMID 25352655, PMID 29802530, PMID 31364269, PMID 38770818, PMID 1244564, PMID 1563586, PMID 16033281, PMID 16612330, PMID 17098089, PMID 17337495, PMID 17387446, PMID 17622601, PMID 18539916, PMID 18539917, PMID 18784090, PMID 19336687, PMID 20092585, PMID 20388897, PMID 21206136, PMID 21332627, PMID 21342412, PMID 21562064, PMID 21562067, PMID 22025647, PMID 22081481, PMID 22093196, PMID 22192246, PMID 22313154, PMID 22446170, PMID 22517736, PMID 22668067, PMID 22804249, PMID 22828124, PMID 23020253, PMID 23384119, PMID 23439165, PMID 23524641, PMID 23563279, PMID 23564755, PMID 23638466

NIH funding

2015 (3), 1UH3TR001372-01 (1), 2014 (1), 2018 (1), R01DK024092 (1)